Back to Search
Start Over
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) in Atopic Dermatitis
- Source :
- PR Newswire. October 19, 2020
- Publication Year :
- 2020
-
Abstract
- - In three pivotal Phase 3 studies, RINVOQ met co-primary and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis[1-3] - Also known as eczema, [...]
- Subjects :
- United States. Food and Drug Administration -- Technology application
Allergan PLC -- Technology application
AbbVie Inc. -- Technology application
Medical research -- Technology application
Medicine, Experimental -- Technology application
Atopic dermatitis -- Technology application
Adalimumab -- Technology application
Drug approval -- Technology application
Pharmaceutical industry -- Technology application
Technology application
Business
News, opinion and commentary
Rinvoq (Medication)
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.638814942